The year 2020 brought the onslaught of a global crisis in the form of the COVID-19 pandemic. While nearly every facet of everyday life and work was impacted by the pandemic, the biopharmaceutical industry found silver linings in innovation, partnership, and resiliency, all of which contributed to unprecedented speed in developing and delivering vaccines and therapies. The 7th International Conference on Accelerating Biopharmaceutical Development (AccBio 2021) brought together industry leaders to share experiences from the past year and discuss how lessons learned from the pandemic can be carried forward into the future of biopharmaceutical development. Presenters highlighted examples such as introducing biotherapeutics derived from non-clonal cell pools into the clinic, developing modular or platform technologies, and taking novel risks, among others. These strategies for enabling speed to clinic and launch, as well as for sustaining a robust supply chain, are likely to be integrated into future programs to ensure biomanufacturing resiliency and get medicines to patients faster than pre-pandemic times.

中文翻译：

---

未来的大流行和复原力：AccBio 2021

2020 年以 COVID-19 大流行的形式带来了全球危机的冲击。尽管日常生活和工作的几乎每个方面都受到了大流行的影响，但生物制药行业在创新、合作伙伴关系和弹性方面发现了一线希望，所有这些都有助于以前所未有的速度开发和提供疫苗和疗法。第七届加速生物制药发展国际会议（AccBio 2021）汇聚了行业领导者，分享过去一年的经验，并讨论如何将从大流行中吸取的教训推广到生物制药发展的未来。演讲者强调了一些例子，例如将来自非克隆细胞池的生物治疗药物引入临床，开发模块化或平台技术，以及承担新的风险，其中。这些加快临床和上市以及维持强大供应链的策略很可能会被整合到未来的计划中，以确保生物制造的弹性并比大流行前更快地为患者提供药物。